Harrow, Inc. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
Harrow, Inc. (HROW) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $2.47 million for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-12.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2015-03-12
- Harrow, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2014 was $2.47M.
- Harrow, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2012 was $2.16M, a 1115.53% increase from fiscal 2011.
- Harrow, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2011 was $177.42K, a 66.89% decline from fiscal 2010.
- Harrow, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2010 was $535.81K, a 38.08% increase from fiscal 2009.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|
| 2014-12-31 | $2.47M 10-K · filed 2015-03-12 |
| 2012-12-31 | $2.16M 10-K · filed 2013-03-18 |
| 2011-12-31 | $177.42K 10-K · filed 2013-03-18 |
| 2010-12-31 | $535.81K 10-K · filed 2013-03-18 |
| 2009-12-31 | $388.05K 10-K · filed 2013-03-18 |
| 2008-12-31 | $562.44K 10-K · filed 2014-03-28 |
| 2007-12-31 | $184.52K 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |